Market revenue in 2023 | USD 318.7 million |
Market revenue in 2030 | USD 823.3 million |
Growth rate | 14.5% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.39% in 2023. Horizon Databook has segmented the India circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Indian branded generics market is anticipated to witness significant market growth over the coming years. Government initiatives such as Pradhan Mantri Bhartiya Janaushadhi Pariyojana, Ayushman Bharat, and PMNRF may improve public access to treatments, encouraging generic players.
Unbranded generics in India are associated with various misconceptions, including distrust of product quality and effectiveness. Owing to this, there is an opportunity for branded generics players to strengthen their market share in the Indian market.
In addition, physicians are not bonded with any law for prescribing medicine in India. Due to this, several branded generics companies use local sales force to promote their products in the market. All these factors are expected to support market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the India circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into India circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account